{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:26:30Z","timestamp":1790270790665,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Unit at Dubai Medical College"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background\u00a0and Objectives: Migraine is a chronic neurological disorder affecting approximately 14% of the global population. Beyond physical pain, migraines significantly impact individuals\u2019 quality of life, influencing education, employment, and income levels. Topiramate, a second-generation antiepileptic medication, has demonstrated notable efficacy in reducing the occurrence of chronic migraine. Over the past three decades, extensive research has implicated the neuropeptide calcitonin gene-related peptide (CGRP) in migraine pathogenesis. Erenumab, the first FDA-approved CGRP inhibitor, received approval in 2018. This study aims to compare the clinical efficacy of Erenumab and Topiramate for migraine prevention. Materials and Methods: We conducted a retrospective cohort study of adults with episodic or chronic migraine over a 12-month period, comparing Erenumab (n = 52) and Topiramate (n = 56). Outcomes assessed included changes in the Migraine Disability Assessment (MIDAS) scores from baseline over the last three months of treatment and the proportion of patients achieving a \u226550% reduction in MIDAS scores by the end of the study. Results: The Erenumab group showed significant improvement, with nearly 79% of patients achieving a 50% reduction in their MIDAS score, with a mean reduction of 3.76. Notably, only two patients (3.8.5) discontinued treatment due to adverse events. In contrast, the Topiramate group had over 15% of patients achieve a 50% reduction in MIDAS scores, with a mean reduction of 5.89, and a had discontinuation rate of 14.2% due to adverse events. Conclusions: Both Topiramate and Erenumab are effective for migraine prevention. However, Topiramate has lower tolerability and more side effects, while Erenumab offers better tolerability and safety at a higher cost. Treatment decisions should be individualized based on patient needs, efficacy, safety, and cost considerations.<\/jats:p>","DOI":"10.3390\/medicina60101684","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T05:47:58Z","timestamp":1728884878000},"page":"1684","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Tolerability of Erenumab and Topiramate for Prevention of Chronic Migraine: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-1749","authenticated-orcid":false,"given":"Eslam El","family":"Nebrisi","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Dubai Medical College for Girls, Dubai 20170, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainaba Suaad Ahmed","family":"Ruwayya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dubai Medical College for Girls, Dubai 20170, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalya Ibrahim","family":"Alzayori","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dubai Medical College for Girls, Dubai 20170, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranya Ibrahim","family":"Alzayori","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dubai Medical College for Girls, Dubai 20170, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Babu","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zulekha Hospital, Dubai P.O. Box 48577, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4266-5620","authenticated-orcid":false,"given":"Mohamed","family":"Elshafei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zulekha Hospital, Dubai P.O. Box 48577, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref_1","unstructured":"(2024, January 08). Migraine|National Institute of Neurological Disorders and Stroke, Available online: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/migraine."},{"key":"ref_2","unstructured":"(2024, January 08). Migraine-Symptoms and Causes. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/migraine-headache\/symptoms-causes\/syc-20360201."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The Global Prevalence of Headache: An Update, with Analysis of the Influences of Methodological Factors on Prevalence Estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, Regional, and National Burden of Migraine in 204 Countries and Territories, 1990 to 2019","volume":"163","author":"Safiri","year":"2022","journal-title":"Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-823356-6.00017-2","article-title":"Chapter 3\u2014Epidemiology of Migraine","volume":"Volume 198","author":"Swanson","year":"2023","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Amiri, P., Kazeminasab, S., Nejadghaderi, S.A., Mohammadinasab, R., Pourfathi, H., Araj-Khodaei, M., Sullman, M.J.M., Kolahi, A.-A., and Safiri, S. (2022). Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.800605"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rustom, A., Audi, F., Samsam, H., Nour, R., Mursi, A., and Mahmoud, I. (2022). Migraine Awareness, Prevalence, Triggers, and Impact on University Students: A Cross-Sectional Study. Egypt J. Neurol. Psychiatry Neurosurg., 58.","DOI":"10.1186\/s41983-022-00555-w"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/head.13613","article-title":"Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"59","author":"Buse","year":"2019","journal-title":"Headache J. Head Face Pain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","article-title":"Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse\/Domestic Partner in the CaMEO Study","volume":"Volume 91","author":"Buse","year":"2016","journal-title":"Mayo Clinic Proceedings"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/03331024221123058","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the Preventive Treatment of Chronic Migraine: A Meta-Analysis on 10 Years of Real-World Data","volume":"42","author":"Ducros","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"MIGR-001 Study Group Topiramate in Migraine Prevention: Results of a Large Controlled Trial","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_12","unstructured":"(2024, January 08). Topiramate. Available online: https:\/\/go.drugbank.com\/drugs\/DB00273."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","article-title":"Calcitonin Gene-Related Peptide (CGRP): Role in Migraine Pathophysiology and Therapeutic Targeting","volume":"24","author":"Wattiez","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin Gene-Related Peptide: Physiology and Pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1177\/0333102418786261","article-title":"Current Understanding of Trigeminal Ganglion Structure and Function in Headache","volume":"39","author":"Messlinger","year":"2019","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2022-3-5","DOI":"10.7573\/dic.2022-3-5","article-title":"Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists for the Acute Treatment of Migraines in Adults","volume":"11","author":"Ocheretyaner","year":"2022","journal-title":"Drugs Context"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40120-022-00370-8","article-title":"Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety","volume":"11","author":"Lattanzi","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s42399-024-01644-y","article-title":"Divalproex, Valproate, & Developing Treatment Options for Cluster Headache Prophylaxis: Clinical Practice Considerations","volume":"6","author":"Orvin","year":"2024","journal-title":"SN Compr. Clin. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3331024231156922","DOI":"10.1177\/03331024231156922","article-title":"Randomized Controlled Studies Evaluating Topiramate, Botulinum Toxin Type A, and mABs Targeting CGRP in Patients with Chronic Migraine and Medication Overuse Headache: A Systematic Review and Meta-Analysis","volume":"43","author":"Giri","year":"2023","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd Edition. Cephalalgia Int. J. Headache, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_21","unstructured":"(2024, October 04). Headache Management Tools: MIDAS|National Headache Foundation. Available online: https:\/\/headaches.org\/."},{"key":"ref_22","unstructured":"(2024, October 06). The International Classification of Headache Disorders\u2014ICHD-3. Available online: https:\/\/ichd-3.org\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S1474-4422(07)70272-7","article-title":"Cessation versus Continuation of 6-Month Migraine Preventive Therapy with Topiramate (PROMPT): A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"6","author":"Diener","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 Randomized Trial of Erenumab for Episodic Migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-to-Four Previous Preventive Treatments Were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet Lond. Engl."},{"key":"ref_26","unstructured":"(2024, October 04). PRAC Recommends New Measures to Avoid Topiramate Exposure in Pregnancy, Available online: https:\/\/www.aifa.gov.it\/en\/-\/il-prac-raccomanda-nuove-misure-per-evitare-l-esposizione-del-topiramato-in-gravidanza."},{"key":"ref_27","first-page":"16","article-title":"The key role of tubulointerstitium remodeling in progression of chronic renal diseases","volume":"66","author":"Mukhin","year":"2004","journal-title":"Arkh. Patol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.yebeh.2008.12.015","article-title":"Presumed Topiramate-Induced Maculopathy","volume":"14","author":"Beyenburg","year":"2009","journal-title":"Epilepsy Behav. EB"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/089277902753752188","article-title":"Topiramate-Induced Nephrolithiasis","volume":"16","author":"Kuo","year":"2002","journal-title":"J. Endourol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s42399-023-01467-3","article-title":"Carbonation and Sweet Taste Dysgeusia with Topiramate Therapy for Migraine Prevention Treatment: A Case Report","volume":"5","author":"Galassi","year":"2023","journal-title":"SN Compr. Clin. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","article-title":"Safety and Tolerability of Erenumab in Individuals with Episodic or Chronic Migraine across Age Groups: A Pooled Analysis of Placebo-Controlled Trials","volume":"23","author":"Lampl","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in Patients over 65 Years: A Real-Life Multicentre Analysis of 162 Patients","volume":"24","author":"Campoy","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1177\/0333102418789072","article-title":"Migraine-Related Disability, Impact, and Health-Related Quality of Life among Patients with Episodic Migraine Receiving Preventive Treatment with Erenumab","volume":"38","author":"Buse","year":"2018","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-024-01747-w","article-title":"Is Erenumab an Efficient Alternative for the Prevention of Episodic and Chronic Migraine in Spain? Results of a Cost-Effectiveness Analysis","volume":"25","author":"Poveda","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s10194-023-01696-w","article-title":"Clinical Effectiveness of Pharmacological Interventions for Managing Chronic Migraine in Adults: A Systematic Review and Network Meta-Analysis","volume":"24","author":"Naghdi","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s10194-022-01511-y","article-title":"Erenumab versus Topiramate: Post Hoc Efficacy Analysis from the HER-MES Study","volume":"23","author":"Ehrlich","year":"2022","journal-title":"J. Headache Pain"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1684\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:53Z","timestamp":1760112773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["medicina60101684"],"URL":"https:\/\/doi.org\/10.3390\/medicina60101684","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}